Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
Orthopedia (KIDS) is a medical device innovator focused exclusively on pediatric orthopedic solutions, developing specialized implants and surgical instruments for children's unique anatomical needs. This dedicated news hub provides investors, analysts, and healthcare professionals with centralized access to official company announcements and developments.
Find timely updates on financial earnings, product launches, regulatory milestones, and strategic partnerships that demonstrate Orthopedia's leadership in pediatric care innovation. Each press release and news article is curated to deliver actionable insights into the company's operational progress and market positioning.
As a vital resource for tracking advancements in children's orthopedic healthcare, this page offers verified information to support informed decision-making. Bookmark this hub or check back regularly for essential updates directly impacting the evolving landscape of pediatric medical technology.
OrthoPediatrics Corp. reported a 41% increase in revenue for the first quarter of 2024 compared to the same period last year, reaching $44.7 million. The Company helped nearly 28,000 children, with domestic revenue up by 44% and international revenue up by 33%. OrthoPediatrics experienced growth in Trauma & Deformity, Scoliosis, and Sports Medicine/Other revenue streams. The acquisition of Boston Orthotics & Prosthetics enhanced the Specialty Bracing Division. The full year 2024 revenue guidance was increased to $200.0-$203.0 million from $197.0-$200.0 million, showcasing a growth of 34%-36% over the previous year.
OrthoPediatrics Corp. has received the 'Breakthrough Device' Designation from the FDA for its new eLLi Growing Rod System, designed to treat pediatric patients with scoliosis. The device aims to address severe pathology associated with Early Onset Scoliosis, providing increased force, enhanced reliability, and precision, while improving safety. The Breakthrough Program expedites the development and review of medical devices for life-threatening conditions, allowing for timely access to innovative technologies. OrthoPediatrics' CEO, David Bailey, expressed pride in the team's achievement and commitment to advancing pediatric healthcare.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
